gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · RLAYHealthcareBiotechnology

Relay Therapeutics, Inc. Common Stock (RLAY)

$18.03+3.38%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$17.44▲ 151.30% in range
Nov 3, 2025Low $6.05 · High $20.75Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Relay Therapeutics closed at $18.03 on Nov 4, up 3.38%, 13.1% below its 52-week closing high. Volume of 3.7M shares was 1.56× its 20-day average (above normal).

Split-adjusted performance: -3.8% over one month, +39.6% over six months, +159.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $350K, down 48.3% from a year earlier, with a net margin of -23916.3%.

Short interest was 44.0M shares at the Oct 15 settlement, down 5.8% from the prior report (27.9% of float, 16.0 days to cover).

Market cap$3.95B219.1M shares
Revenue · quarter$350.0K−48.3% YoY
Diluted EPS$-0.41—
P/E · TTM—P/S 381.8×
Net margin-23,916.3%Gross 100.0%
Dividend yieldNone
52-week range6.05 – 20.75−13.1% from high
Volume3.7M1.56× 20-day avg
Volatility · 60d49.2%Annualised
Short % of float27.9%16.0 days to cover
Net cash$910.9MCash $910.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −8.4%1M −3.8%3M −8.7%6M +39.6%YTD +113.1%1Y +159.8%3Y +189.4%5Y −40.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum86
Revenue growth25
Net margin6
Value (low P/E)—
Size85

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short44.0M−5.8% vs prior
Days to cover16.0Settled Oct 15
% of float27.9%
Short vol. 10d56.5%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
RLAYRelay Therapeutics$18.03+3.38%+39.6%−48.3%−23916.3%—$3.95B
IOVAIovance Biotherapeutics$8.70−1.47%+112.7%+65.7%−47.6%—$3.94BCompare
ADPTAdaptive Biotechnologies$26.71+3.53%+85.1%+21.5%−55.6%—$4.26BCompare
DNLIDenali Therapeutics$20.96+7.76%+2.7%—−3539.2%—$3.35BCompare
TARSTarsus Pharmaceuticals$69.07−4.91%+6.7%+63.9%−343.5%—$3.23BCompare
CRSPCRISPR Therapeutics AG$51.78+3.57%−6.0%+1325.1%−879.6%—$5.01BCompare
BEAMBeam Therapeutics$27.79+5.54%−14.1%−94.2%−25036.3%—$2.87BCompare
SRRKScholar Rock Holding$46.09+4.80%−2.2%———$5.61BCompare
CGONCG Oncology$67.71+5.70%−0.4%—−6832.8%—$6.00BCompare

News about Relay Therapeutics

All news →
Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment OptionGlobeNewswire Inc. · Sep 23, 2026▲ PositiveRelay Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberGlobeNewswire Inc. · Sep 1, 2026NeutralIs Relay Therapeutics a Buy After Promising Trial Results?The Motley Fool · May 22, 2026▲ PositiveRelay Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire Inc. · May 21, 2026▲ PositiveWhy Relay Therapeutics Stock Popped on WednesdayThe Motley Fool · May 20, 2026▲ Positive

Quick answers

What does Relay Therapeutics do?
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed.
What is RLAY's market cap?
$3.95B, based on the Nov 4 close of $18.03.
Does Relay Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of RLAY is sold short?
44.0M shares, 27.9% of float, as of Oct 15, 2026.
What sector is RLAY in?
Healthcare, in the Biotechnology industry.

About Relay Therapeutics

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.

HQ: Cambridge, MA192 employeesListed Jul 16, 2020relaytx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology